BIIB Share Price

Open 275.59 Change Price %
High 276.71 1 Day -1.12 -0.41
Low 272.50 1 Week -3.76 -1.35
Close 274.11 1 Month -14.49 -5.02
Volume 1147909 1 Year 19.43 7.63
52 Week High 333.65
52 Week Low 223.02
BIIB Important Levels
Resistance 2 278.01
Resistance 1 276.40
Pivot 274.44
Support 1 271.82
Support 2 270.21
NASDAQ USA Most Active Stocks
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
FTR 1.98 -1.98%
FTR 1.98 -1.98%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
ACAS 17.99 0.39%
More..
NASDAQ USA Top Gainers Stocks
AMCF 0.10 100.00%
LOCM 0.09 50.00%
SSH 2.31 32.76%
SSH 2.31 32.76%
SSH 2.31 32.76%
LTRE 2.40 31.87%
HPJ 4.90 30.67%
WRES 0.09 28.57%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
ORIG 0.23 -68.49%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
VALV 0.02 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
More..

Biogen Idec Inc. (NASDAQ: BIIB)

BIIB Technical Analysis 3
As on 28th Mar 2017 BIIB Share Price closed @ 274.11 and we RECOMMEND Sell for LONG-TERM with Stoploss of 285.99 & Sell for SHORT-TERM with Stoploss of 282.64 we also expect STOCK to react on Following IMPORTANT LEVELS.
BIIB Target for March
1st Target up-side 306.85
2nd Target up-side 319.64
3rd Target up-side 332.43
1st Target down-side 270.35
2nd Target down-side 257.56
3rd Target down-side 244.77
BIIB Other Details
Segment EQ
Market Capital 33194547200.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.biogenidec.com
BIIB Address
BIIB
225 Binney Street
Cambridge, MA 02142
United States
Phone: 781-464-2000
BIIB Latest News
Interactive Technical Analysis Chart Biogen Idec Inc. ( BIIB NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Biogen Idec Inc.
BIIB Business Profile
Biogen Idec Inc. (Biogen Idec) is a global biotechnology company. The Company discovers, develops, manufactures and markets therapies for the treatment of neurodegenerative diseases, hemophilia and autoimmune disorders. The Company’s products include AVONEX, TYSABRI, FAMPYRA, FUMADERM and RITUXAN. In September 2011, the Company acquired from the Dompe Group the noncontrolling interests in its joint venture sales affiliates in Italy and Switzerland. In April 2013, Elan Corporation, plc closed the TYSABRI (natalizumab) Collaboration Transaction with Biogen Idec.